500 JouralofNigxiaMedicalUiversity 36 5 2014 5 :1674-6309(2014)05-0500-05 $ A L 1, MNO 2 (1. c, 750004; 2., 750001) : = 2 (SDF)2 )012I,CDB 23 SD) 70E,60E, STZ"2,10E, 0" 2 ) 53E, 2 I(DMI,25E ) SDF'I(SDLI,14E),SDF'I(SDSI, 14E) SDLI) SDF2mg (kg d) -1 +, 125,SDSI) S (APO)" <( SDF20mg (kg d) -1 +, 3d 2J 0-B 4 8 1259+ APO"<,125UT ST bi)i,]^ 45 DMI 01 9+, I 2 5a (P<0.05 P< 0 01) SDLI2 SDSI)01,aV DMI, DMI,45 85 SDLI2 SDS Ib325 ;45 SDLI2 SDSI DMI(SDLI P< 0 05,SDSI P<0.01);85 SDSI DMI(P<0.01) SDSI SDLIb3 1 a (P>0.05) DMII UT T, SDLI,SDSI DMI,a 46 2 SDF3 2 )01 5,, SDFB- SDF2 )I, CD,3 SDF2 )" 789:01S ; 2 ;bc<;) :;:R587 :A 2 01S (diabeticerectile dysfuctio,ded)2 (DM)B= bc<(sildeafilcitrate,sdf)' 01S B58!,!R c2e 1 4 01S (ED) 2 2 )B01 [1-2] 4 &,6 32E* # 2 01B21B CD <S 32 )01B2 I,BCD]^, 9!: 6 3 2E2 )01 2"I,BCD]^ 1 23 1.1 2 D (STZ, sigmat ); bc<(sdf, PQ5 T ); <=>:2013-05-13?@A : L(NZ0674) BCDE:(1978-),,,,c S (APO, SigmaT ) 1.2 <S 2 I 2DB SD) 70 E," (245±25)g,S< ) RY 15, <O -, I(NCI,=10) 2 I (DMI,=30) bc<'i (SDLI,=15) bc<'i (SDSI,=15) 1.3 2 JK SDL SDS DMI) 9N 85-, STZ35mg kg -1 NCI)Y N,,Ebc< MN, STZ72h-, E( (, ( 11.1mmol L -1 = 3d 2 S JK1 J- SDLI) SDF2mg (kg d) -1 +, 125, SDSI) 9+b0 APO" <( SDF20mg (kg d) -1 +, 3d,NC DMI E + 1.4 < P 1.4.1 < 4 8 1259+ APO
53, 2 )"CDB < 501 "<,. Heato 3, APO B P [3] ) U B,X E ) 3, APO,2 E 80μg kg -1 5 /, 3-,!, APO < O X E ) 30mib (XIb3 = <O E /XIE ), ED1 1.4.2 HE2 H-600ST "I 7 "I, 32_`,7!0 108,,QR 4μm<B7 ;17!0 I,7 1mm 1mm 1mm, 4(,ST 1.5 a R SPSS12.0a _`, < ( x±s)@, 珋 I " /g ^(ANOVA), B χ 2 < < α=0.05 2 45 2.1 SDF 2 )B!; ]^2( BCD 60E)c, STZ -,53E 0"2 (DM I 25E,SDL2 SDSIb 14E) <+ W5 19E 2 )\, <# DMI 18E,SDL2 SDS b 8E J 0- DM SDL SDS3I 2 ) /) K N! 8,( ', 125bI)" E E2( 1 @ 1,3Ib1 I 5a (P <0.01) DM I, SDSI2 SDLIb1,a,0 SDF 2 )BN N "' 8, (CD 0 1 SDF 12,' E / [g (d E) -1 ] E / [ml (d E) -1 ] ( / (mmol L -1 ) NC 10 491.20±12.02 42.56±5.32 52.65±6.22 4.30±0.65 DM 18 283.72±25.53 115.8±5.43 112.57±7.71 19.02±2.07 SDL 8 279.67±28.09 123.5±4.56 120.60±9.24 18.21±2.66 SDS 8 290.00±25.79 110.2±6.62 126.26±8.65 18.93±3.02 NCI P<0.01 2.2 SDF 2 ) BCD bi) 3, APO- ]^ @ 2 J- 05bI) 2,I)01,, DMI 9+ ;45 852 125 DMI2 NCI(P <0.01) NCI,SDLI2 SDSI)2 V; 2 I,45 85 I 05 SDLI2 SDSI25,45 SDLI2 SDSI DMI(SDLI P<0.05,SDSI P<0.01);85 SDSI DMI(P<0.01) 2 SDF 1)01, 3"), 8./, SDF'8, SDSI SDLIb3 1 a (P>0.05) 0 2 SDF $ /! 45 85 NC 10 100 3.90±1.20 10 100 3.10±1.45 10 100 2.90±1.20 10 100 2.40±0.70 DM 25 100 3.60±1.26 21 81 1.29±0.90 20 55 0.60±0.60 18 33 0.33±0.49 SDL 14 100 3.50±1.45 10 100 2.40±1.17 9 67 1.00±0.87 8 25 0.25±0.46 SDS 14 100 3.57±1.51 11 100 2.91±1.14 9 78 1.67±1.12 8 50 0.88±1.13 NCI P<0.05, P<0.01; DMI P<0.05), P<0.01 2.3 SDF2 )B ", 2.3.1 UT HEI 7 NCI: 125 /B(-./I 2(#5,( -c(, 4I SDS DMI: /B(-, 4I,(-
502 a 361 UV,cE( SDLI: #5B(-,0 (- UV, EB 4I, DMI \ 1( 3) 2.3.2 T NCI: /B(- Z; Z 4I #5 c3 Z4, Z )*,NE4,Z K ; Z; Z4, 4I/ DM I SDSI: /B(-,c3 Z,Z4, cc4 2 Y"Z,4,4 ;c3 Z, N, (- c,(-v; 4I, Z; Z,Z,K,4) ; FE #, SDLI: DM I, 4I E, Z; Z9!:, FE #,ce N B Z,#5B(-,E,N #5B(-,,0Z4,Z4,,[\ Z20 B 4, \ 2( 3) 3 M6 8< Q2 SDF[,!B ' EDB, + Q NOB8< I NO B E, 9( &L' SDF ' ED0,, DEDB8 EL-Galey 2002U @a2,48 SDF2U-F$&, F $&8;15 37 B '8B[, 2E ' 8 [4] +,@2",-c3 Z,"? <, F=#5-&, " Z; F," R [5-6] 4, DEDB$, ' 8 &8BF$ ( SDF DED'8] B,FMotorsi /,Y SDF,R SDF!UB,4E 3 [7] c I 2E1 4 ED2 2 )B01 [1-2] Ostafa Helmy ) 32E 2 2 B B ) 0 1 5 [8-9] 4 2 &(65),132E SDF DEDB'82IB CD 15 I 45 2E SDF )I BCD,# )" 4a I [10] 4]^,\ +S< B P, 2 SDF 2 )01BCD,! 2 )01CDB, 6 4 2 )"I,a]^ <# @, (( )2 2E SDF3 2 )B0 15B, B,'8. /, EL-GaleyB#! [4] ^ F$, 23 EDBF $ ( c301,2 L( 4,a,(L, " P (&L,S 1( c301, NOB, 9(L,1 '8-3, <B,125 2 )I,c3 Z, Z; Z, 4a, FE #,BI #5 B, NOB 1 'B 2 5 BI! SDF ' DED'8 2&8BF$! 2 ED, 'BR*,QF,' "I,!,3 101B, 2,! BV,!I a1 $ EB < SDF -3 5@)/B, 2 I01 9!: 85 SDLI 2 SDSI, 125 5@)/ 01B, I),125 SDLI) I DMI,01 Z E &,"I #5,-#5
53, 2 )"CDB < 503,0 E \ Z,/)!B 4),BI #5 &!) <B I )01BF$2 "I,, 2E B"I,B8R 4# /)B1!F$ < SDS II,a DMI, 0)I, C D #2"3 2E 2 ", * )5 CD 9!: 4, SDF3 2 ) 015,, *2 ),a CD * 3 2 )01 5,8,3 2 ), DEDB ' ' DEDB,Q(,,' M B C NO: [1] FeriiMG,KovaeczI,SachezS,etal.Log-term cotiuoustreatmetwithsildeafilamelioratesagig -relatederectiledysfuctioadtheuderlyigcor poralfibrosisitherat[j].biolreprod,2007(5):76: 915-923. [2]?,N.2E ' 4 01S 17 [J]. I,2012, 28(14):2441-2442. [3] HeatoJPW,VariS,MoralesA,etal.Thecharacter izatioofabioasayoferectilefuctioiaratmodel [J].JUrol,1991,145(5):1099-1102. [4] REl-Galey,HRutlad,RTalic,etal.Logtermefi cacyofsildeafiladtachyphylaxisefect[j].jurol, 2002(166):927-931. [5] SalamaN,KagawaS.Ultra-stucturalchagesicola geofpeiletuuicaalbugieaiagedaddiabeticrats [J].ItJImpotRes,1999,11(2):99-105. [6],LN,,. 201 S )JK"6 #5B[J].C 2I,1999,20(10):628-631. [7] FMotorsi,BVerheyde,EMeulema,etal.Log- termsafetyadtolerabilityoftadalafilithetreatmet oferectiledysfuctio[j].eururol,2004,45(3): 339-345. [8] MostafaT,RashedLA,KotbK.Testosteroeadchro icsildeafil/tadalafilati-apoptoticroleiageddia beticrats[j].itjimpotres,2012,22(4):255-261 [9] HelmyMM,SebelAM.EvaluatioofvitamiEithe treatmetoferectiledysfuctioiagedrats[j].life Sci,2012,90(13-14):489-494. [10] BGumus,HSVatasever,TMuezioglu,etal.His topathologicalefectsofsildeafilcitrateoratcorpus caverosum[j].actahistochemica,2004(106): 37-45. (^ _`: ) HarmfulEfectsofChroicTreatmetwithSildeafilCitrate opathologicalijuryofpeisidiabeticrats CHENLig 1, LIGuohui 2 (1.TheGeeralHospitalofNigxiaMed.Uiv.,Yichua750004; 2.TheTraditioal ChieseMedicieHospitalofYichua,Yichua750001) Abstract:Objective Toexploretheefectsofthechroictreatmetwithsildeafilcitrate(SDF)oerectile dysfuctioadhistopathologicalijuryofcorpuscaverosum idiabeticratsadtocomparediferecebe tweecotiuousaddiscotiuoussdfitervetioodiabeticratspeileerectilefuctioadthetisuele sios.methods 60maleSDratsaccepteditraperitoealijectioofSTZtoiducediabetes.Thediabetic ratsweredivideditocotiuoustreatmetgroup(sdl,=14),itermitettreatmetgroup(sds,=14), o-treatmetgroup(dm,=25)adormalratswereusedasthecotrol(nc,=10).ratsigroupsdl receivedsdf2mg (kg d) -1 bygavagesfor12weeks.ratsigroupsdsreceivedsdf20mg (kg d) -1 forthreedayjustbeforeapotest.at4,8,12weeksapoiducepeileerectileexperimetwascariedout. Thepathologicalchagesofpeiswereobservedbyusiglightmicroscopeadelectromicroscope.Results
504 a 361 PeileerectilefuctioprogresivedecliediDMgroup.Comparedwithormalcotrolgroup,ratesadfre queciesoferectiodecreasedsigificatly.ratpeileerectilefuctiochagetredisdladsdsgroup showedthesameasthatidiabetesgroup.frequeciesoferectioisdladsdsgroupat4weekwere higherthathoseofdm groupwhileolyerectiletimesisdsat8weekwerehigherthathatidm group (P<0.01).Coclusio ChroictreatmetwithSDFcaameliorateerectilefuctioofdiabeticratsjustat earlystageadthecurativeefectswerelowerthashort-termtreatmet.log-termtreatmetwithsdfag gravatedthecaverosumpathologicallesioidiabeticrats. Keywords:erectiledysfuctio;diabetes;sildeafilcitrate;rat ( 499) [13],,H],. ( 7` +JK MMP-1,MMP-132 TIMP-1B mrna@a[j].ci,2002,6 (3):169-172. [14] L Q,>V,,.@ A` + (= IGF-1 TGF-β FGF-2@A CDB[J].a,2013,35(2): 177-180. [15],LV. @ 'A` +B < ^[J].,2012,43(2):56-58. (^ _`: ) EfectsofNeedleWarmigMoxibustiooSerum MMP-1,MMP-13 LevelitheKeeOsteoarthritisofRabbits LIUDi 1, WUYogli 2, ZHANGYalig 1, XUJiafeg 2, MAXiaoxiu 1, LUZogzhi 2 (1.NigxiaMed.Uiv.,Yichua750004; 2.Dept.ofChieseOrthopedics,the GeeralHospitalofNigxiaMed.Uiv.,Yichua750004) Abstract:Objective Toivestigatetheiflueceofeedlewarmigmoxibustioomatrixmetaloproteases adhistomorphologyoftherabbitexperimetalkeeosteoarthritismodel,adtoexploreitsrelativemecha ism.methods 30malerabbitswereradomlydivideditomodel,eedlewarmigmoxibustioadwester mediciegroup,eachgroupof10cases.thecocetratiosofmmp-1,mmp-13iserumweredetectedby ELISAaftertwoweekstreatmet.Results Thecartilagebecamethiigadappearedasigificatarticular ijury.needlewarmigmoxibustio group ca improvethehistologicalstructureofarticularcartilage. MMP-1adMMP-13beforetreatmetwereicreasedsigificatlycomparedwithormale(P<0 05). Comparedwithmodelgroup,bothMMP-1adMMP-13levelsiwarm acupucture-moxibustiogroup werereducedcosiderably(p<0.05).nosigificatdifereceswerefoudbetweewestermedicatio groupadmodelgroup,westermedicatiogroupadeedlewarmigmoxibustiogroup.coclusio MMP-1,MMP-13participateditheoccureceofKOAadeedlewarmigmoxibustiocatreatKOAar ticularijury,whichmayrelatedwiththeexpresioofmmp-1,mmp -13. Keywords:keeosteoarthritis;eedlewarmigmoxibustio;MMP-1;MMP-13